Please use this identifier to cite or link to this item: https://doi.org/10.1111/1756-185X.12685
DC FieldValue
dc.titleSingapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis
dc.contributor.authorLahiri, M
dc.contributor.authorTeng, GG
dc.contributor.authorCheung, PP
dc.contributor.authorSuresh, E
dc.contributor.authorChia, FL
dc.contributor.authorLui, NL
dc.contributor.authorKoh, DR
dc.contributor.authorKoh, WH
dc.contributor.authorLeong, KP
dc.contributor.authorLim, AYN
dc.contributor.authorNg, SC
dc.contributor.authorThumboo, J
dc.contributor.authorLau, TC
dc.contributor.authorLeong, KH
dc.date.accessioned2021-11-23T05:05:24Z
dc.date.available2021-11-23T05:05:24Z
dc.date.issued2017-10-01
dc.identifier.citationLahiri, M, Teng, GG, Cheung, PP, Suresh, E, Chia, FL, Lui, NL, Koh, DR, Koh, WH, Leong, KP, Lim, AYN, Ng, SC, Thumboo, J, Lau, TC, Leong, KH (2017-10-01). Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis. International Journal of Rheumatic Diseases 20 (10) : 1527-1540. ScholarBank@NUS Repository. https://doi.org/10.1111/1756-185X.12685
dc.identifier.issn17561841
dc.identifier.issn1756185X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/207378
dc.description.abstractAim: In Singapore, patients with psoriatic arthritis (PsA) constitute a significant disease burden. There is good evidence for the efficacy of anti-tumor necrosis factor (anti-TNF) in PsA; however cost remains a limiting factor. Non-biologic disease modifying anti-rheumatic drugs (nbDMARDs) hence remain the first-line treatment option in PsA in spite of limited evidence. The Singapore Chapter of Rheumatologists aims to develop national guidelines for clinical eligibility for government-assisted funding of biologic disease modifying anti- rheumatic drugs (bDMARDs) for PsA patients in Singapore. Methods: Evidence synthesis was performed by reviewing seven published guidelines on use of biologics for PsA. Using the modified Research and Development/University of California at Los Angeles Appropriateness Method (RAM), rheumatologists rated indications for therapies for different clinical scenarios. Points reflecting the output from the formal group consensus were used to formulate the practice recommendations. Results: Ten recommendations were formulated relating to initiation, continuation and options of bDMARD therapy. The panellists agreed that a bDMARD is indicated if a patient has active PsA with at least five swollen and tender joints, digits or entheses and has failed two nbDMARD strategies at optimal doses for at least 3 months each. Any anti-TNF may be used and therapy may be continued if an adequate PsARC response is achieved by 3 months after commencement. Conclusion: The recommendations developed by a formal group consensus method may be useful for clinical practice and guiding funding decisions by relevant authorities in making bDMARD usage accessible and equitable to eligible patients in Singapore.
dc.sourceElements
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Rheumatoid
dc.subjectFinancing, Government
dc.subjectHumans
dc.subjectPractice Guidelines as Topic
dc.subjectSingapore
dc.typeArticle
dc.date.updated2021-11-20T13:46:49Z
dc.contributor.departmentDEAN'S OFFICE (MEDICINE)
dc.contributor.departmentMEDICINE
dc.contributor.departmentPHYSIOLOGY
dc.description.doi10.1111/1756-185X.12685
dc.description.sourcetitleInternational Journal of Rheumatic Diseases
dc.description.volume20
dc.description.issue10
dc.description.page1527-1540
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Int J Rheum Dis 2015 Lahiri.pdf146.61 kBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.